After one year of the COVID-19 pandemic, several working vaccines have been successfully brought to market, and are making it into the arms of millions around the world. Telehealth and telemedicine services saw a boom in the past year as providers and patients alike adapted to the new normal of remote engagement. Yet, M&A deal value declined by 37% in 2020 representing roughly 9% in overall deal volume in the industry compared to 2019. What can the industry expect with the new Biden Administration in terms of new regulatory policies?
Are private equity investors expecting deal volume to accelerate in 2021? How much of this will vary by sub-sectors e.g. biotech/pharma, teleservices etc? What opportunistic acquisitions are in the market for buyers now? Will the addition of new vaccine candidates be favorable for the market? How are investors addressing the health disparity and access issues that COVID-19 and vaccine roll-out are amplifying?
Featured panelists:
The Honorable Eric D. Hargan, Former US Deputy Secretary, Health and Human Services (Moderator)
Adam Blumenthal, Founder and Managing Partner, Blue Wolf Capital Partners
Matt Holt, Managing Director and President, Private Equity, New Mountain Capital
Bill Lee, Senior Vice President and Chief Investment Officer, New York Presbyterian Hospital
#RFKCompass #InvestorActivism #ESGInvesting
source